All In Biotech

Drug Trial Radar · NCT07598396

A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 25, 2026

Primary completion

Aug 11, 2028

Study completion Aug 11, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess how mosunetuzumab works in people who have systemic lupus erythematosus (SLE) who may or may not also have active lupus nephritis (LN).

Conditions

  • Lupus
  • Systemic Lupus Erythematosus
  • Lupus Nephritis

Interventions

  • MosunetuzumabDrug

    Participants will receive SC mosunetuzumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who have achieved remission by Week 76Time frame: Up to Week 76

Locations

24 sites in 6 countries. Site status is shown where the registry gives one.

  • Organizacion Medica de Investigacion (OMI)

    CABA, Buenos Aires, Argentina · Recruiting

  • APRILLUS Asistencia e Investigacion

    Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Clnica SER da Bahia

    Salvador, Estado de Bahia, Brazil · Recruiting

  • L2IP ?Instituto de Pesquisas Clínicas Ltda.

    Brasília, Federal District, Brazil · Recruiting

  • IPC MT Instituto de Pesquisas Clinicas do Mato Grosso

    Cuiab, Mato Grosso, Brazil · Recruiting

  • Complexo Hospitalar de Niteroi

    Niterói, Rio de Janeiro, Brazil · Recruiting

  • LMK Servios Mdicos S/S Ltda

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital das Clinicas de Ribeirao Preto

    Ribeiro Preto, São Paulo, Brazil · Recruiting

  • Hospital das Clnicas da Faculdade de Medicina da USP

    São Paulo, São Paulo, Brazil · Recruiting

  • Clinica de la Costa S.A.S

    Barranquilla, Colombia · Recruiting

  • Administradora Country S.A.S.

    Bogotá, Colombia · Recruiting

  • Centro de Investigacion en Reumatologia y Especialdades Medicas SAS. CIREEM

    Bogotá, Colombia · Recruiting

  • Hospital Pablo Tobon Uribe

    Medellín, Colombia · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, Lazio, Italy · Recruiting

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)

    Brescia, Lombardy, Italy · Recruiting

  • Istituto Clinico Humanitas

    Rozzano, Lombardy, Italy · Recruiting

  • CIMAB S.A. de C.V.

    Torreón, Coahuila, Mexico · Recruiting

  • Centro Medico del Angel

    Mexicali, Estado de Baja California, Mexico · Recruiting

  • CREA de Guadalajara, S.C.

    Guadalajara, Jalisco, Mexico · Recruiting

  • Centro de Investigación y Tratamiento Reumatológico S.C.

    México, Mexico CITY (federal District), Mexico · Recruiting

  • Centro de Investigación de Tratamientos Innovadores de Sinaloa (CITI)

    Culiacán, Sinaloa, Mexico · Recruiting

  • Emmed Research

    Pretoria, Gauteng, South Africa · Recruiting

  • University of Cape Town Kidney and Hypertension Research Unit

    Cape Town, Western Cape, South Africa · Recruiting

  • Clinical Trials Network Helderberg

    Somerset West, Western Cape, South Africa · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.